Peer-reviewed veterinary case report
Survival of dogs with mesothelioma treated with chemotherapy
By Lajoinie, Mathilde et al.·Published in Veterinary and comparative oncology·2022·Service de cancé, France·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Outcome of dogs treated with chemotherapy for mesothelioma: A retrospective clinical study on 40 cases and a literature review.
- Species:
- dog
Plain-English summary
A group of 40 dogs diagnosed with mesothelioma, a rare type of cancer, were studied to see how chemotherapy affected their survival. Out of these dogs, 27 received chemotherapy while 13 did not. The results showed that dogs treated with chemotherapy lived significantly longer, averaging about 366 days compared to just 74 days for those who did not receive treatment. Additionally, dogs that had a complete resolution of fluid buildup after their first chemotherapy session had an even better survival rate. Overall, chemotherapy was found to be the most important factor in improving survival for these dogs.
People also search for: dog mesothelioma treatment · chemotherapy for dog cancer · dog cancer survival rates · what is mesothelioma in dogs · dog fluid buildup treatment
Abstract
Mesothelioma is an uncommon cancer in dogs for which there is no established standard of care. Chemotherapy is often suggested despite no definitive proof of efficacy. The aim of this study was to evaluate the impact of chemotherapy on survival of dogs with mesothelioma. A retrospective multicentric study was carried out. To be included, dogs needed to present an evocative clinical evolution and a morphological diagnosis of mesothelioma. Exclusion of other cause of effusion and complete clinical follow-up were also required. Fourty dogs were included, 27 received chemotherapy (group 1) and 13 did not (group 2). Groups were heterogeneous regarding the proportion of animals undergoing surgery as part of their treatment (16 in group 1, 2 in group 2; p = .016) and homogeneous otherwise. Univariate analysis showed that dogs from group 1 survived significantly longer than dogs from group 2 (MST: 366 vs. 74 days; p < .001). Complete resolution of effusion after the first chemotherapy administration positively correlated with survival in group 1 (MST: 415 vs. 160 days; p < .01). All other variable tested had no significant impact on survival in univariate analysis, but dogs undergoing surgery and dogs having serous membranes' modification at medical imaging tended to survive longer. Multivariate analysis confirmed that chemotherapy was the sole variable independently associated with survival in our study (odds ratio 5.57-6.12; p < .01).
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/35633310/